Novo Nordisk
2025.01.29
03:32
Novo Nordisk: The U.S. Food and Drug Administration (FDA) approved Ozempic to reduce the risk of worsening kidney disease. Ozempic can be used to reduce the risk of death from heart disease.
2025.01.24
22:31
U.S. stocks opened, with the Dow Jones Industrial Average down 0.07%, the S&P 500 Index up 0.03%, and the Nasdaq Composite Index up 0.15%. Novo Nordisk (NVO.N) rose 10.62% after clinical trials showed that its weight loss drug Amycretin can reduce weight by 22%. Meta Platforms (META.O) fell 0.19%, CEO Zuckerberg plans to significantly expand the artificial intelligence team. Nvidia (NVDA.O) rose 1%.
20:47
Novo Nordisk shares extend gains, up 14% pre-market
Novo Nordisk shares extended their gains, rising 14% in premarket trading.
18:41
Novo Nordisk (NVO.N) shares rose more than 8% in pre-market trading in the U.S. as clinical trials showed its weight loss drug Amycretin reduced body weight by 22%.
18:38
Novo Nordisk's US stock rose more than 8% before the market opened. Clinical trials showed that its weight loss drug Amycretin reduced body weight by 22%.
Novo Nordisk's US stock rose more than 8% in pre-market trading. The company announced the results of a Phase 1b/2a clinical trial for Amycretin. Patients treated with Amycretin lost 9.7% of their body weight after 20 weeks, 16.2% after 28 weeks, and 22.0% after 36 weeks. Based on this result, Novo Nordisk is planning to further develop Amycretin for overweight or obese adults.
2025.01.18
18:47
Novo Nordisk: Phase 3 clinical trial of 7.2mg semaglutide reached the primary endpoint, with a 20.7% weight loss in 72 weeks
On January 17, local time, Novo Nordisk announced the main results of the Phase 3b clinical trial STEP UP. In the STEP UP obesity trial, once-weekly subcutaneous injection of 7.2 mg semaglutide resulted in a 20.7% weight loss at 72 weeks and an 18.7% weight loss regardless of treatment compliance. The trial met its primary endpoint, with 7.2 mg of semaglutide demonstrating statistically significant and superior weight loss compared with placebo at week 72.
2025.01.17
21:29
LVMH surpasses Novo Nordisk to regain its position as Europe's largest listed company.
21:03
Novo Nordisk's weight loss drugs Ozempic and Wegovy are in the spotlight in Medicare price negotiations.
2025.01.11
18:48
The world's first oral GLP-1RA Novoxin (semaglutide tablets) is fully launched in China
Novo Nordisk announced that the world's first oral glucagon-like peptide-1 receptor agonist (GLP-1RA) - Novoxin (semaglutide tablets) has been fully launched in China. With its convenient oral administration method, Novoxin helps patients benefit from GLP-1RA drugs earlier, helps achieve high-quality blood sugar targets and comprehensive metabolic management, and brings an innovative category to the clinical treatment of type 2 diabetes in China.
2024.12.30
15:58
Gan & Lee Pharmaceuticals: GZR18 Phase III clinical trial in China completes first subject dosing
Gan & Lee Pharmaceuticals announced that its independently developed GZR18 is currently undergoing Phase III clinical trials in China, and the first subject was successfully dosed recently. GZR18 is a long-acting glucagon-like peptide-1 receptor agonist designed to treat type 2 diabetes in adults and weight management in obese/overweight individuals. As of the date of the announcement, the weekly formulations of GLP-1 receptor agonists used for blood sugar control in patients with type 2 diabetes and weight control in obese/overweight patients in China mainly include Novo Nordisk's semaglutide. In the first three quarters of 2024, semaglutide sales in China were DKK 4.913 billion, of which Wegovy® for weight control had sales of DKK 166 million in China. As of September 30, 2024, Gan & Lee Pharmaceuticals has invested a total of RMB 284 million in research and development expenses in the GZR18 injection project.
2024.12.23
22:33
Novo Nordisk rebounded by more than 4%
Novo Nordisk rebounded more than 4%, as analysts said the company's weight loss drugs are still the most effective.
16:08
Novo Nordisk's European shares rose 6.2%, on track for their best performance since August.
16:04
Novo Nordisk shares opened up 6% in Europe
Novo Nordisk's European shares opened 6% higher.
2024.12.20
22:33
Eli Lilly (LLY.N) rose more than 4% as rival Novo Nordisk's weight loss drug trial results fell short of expectations.
19:33
Novo Nordisk spokesperson: The Cagrisema trial allowed for dose reduction; even though only 57% of Cagrisema patients reached the highest dose, statistically significant results were achieved.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.

2025-01-31

White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.

2025-02-01

Apple (AAPL.O) said the Apple Pay outage has been resolved.

2025-01-29

Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.

2025-01-30

Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.

2025-02-03

ASIA TECH WIRE

Grasp technology trends

Download